MYGN News 37.97 Myriad Genetics (MYGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Myriad Genetics (MYGN) 37.97 $MYGN

Edwards Lifesciences Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:30PM CDT
Zacks Investment Research upgraded Edwards Lifesciences to a Zacks Rank #2 (Buy).

Myriad Genetics Is Saving Lives With New Products
at Investor's Business Daily - Thu Apr 17, 2:50PM CDT
Specialties are in vogue at many companies these days, but there's always room for diversifying products, generating revenue streams and expanding the clientele. Proving that point is Myriad Genetics, a molecular diagnostic company based in Salt Lake...

ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:44AM CDT
ImmunoGen, Inc. was a big mover last session, as the company saw its shares surge 11% on the day.

Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:44AM CDT
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.

Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

The Global Market for Biomarkers: Concise Analysis of the $25 Billion Industry
M2 - Tue Apr 15, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7r264/the_global_market) has announced the addition of the "The Global Market for Biomarkers: Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers" report to their offering. The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline. Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body's tissues, and can suggest a cardiovascular event when levels are high. The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report. The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems - Abbott Laboratories - Affymetrix - Agendia - Alere - Beckman Coulter - Becton Dickinson - Biocartis SA - Biodesix - bioMerieux - BioReference Laboratory - bioTheranostics - CardioDX - Celera Alameda - Clarient - deCODE Genetics - DiaGenic - Genomic Health - Johnson & Johnson - Life Techologies - Memory Dx - Myriad Genetics - Nanostring Technologies - OPKO Health - Provista Dx - Qiagen - Roche - Seimens Healthcare - Tethys Bioscience - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/r7...bal_market

Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend

Quest Diagnostics Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:32PM CDT
Adjusted earnings per share of Quest Diagnostic came in at $1.03, beating the Zacks Consensus Estimate of 94 cents by 9.6%, and exceeding the company's prior-year earnings by 2%.

Laboratory Service Providers Should Profit From This New Revenue Source
Bob Chandler, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Medical testing leaders such as Laboratory Corporation of America and Quest Diagnostics have disappointed investors with little to no sales and profit growth over the past couple years. Sluggish demand and collapsing prices have smothered...

Can Honeywell (HON) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:20AM CDT
Honeywell is set to report first-quarter financial results before the market opens on Apr 17, 2014.

Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:20PM CDT
Qiagen acquires an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna.

Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.

Baxano Surgical, Inc. (BAXS) in Focus: Stock up 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:44AM CDT
Baxano Surgical, Inc. was a big mover last session, as the company saw its shares rise nearly 11% on the day.

Investors are betting against Myriad (MYGN), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:02AM CDT
Investors are betting against Myriad (MYGN), Should You?

Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 11.06% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:44AM CDT
Enzymotec Ltd. was a big mover last session, as the company saw its shares rise a little over 11% on the day.

Myriad Genetics Falls 1.34% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Apr 09, 4:35PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $38.83 to a high of $40.75. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $39.54 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

SmarTrend Watching for Potential Rebound in Shares of Myriad Genetics After 1.34% Loss
Comtex SmarTrend(R) - Wed Apr 09, 4:34PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $38.83 to a high of $40.75. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $39.54 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

The Nasdaq's 3 Most Hated Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 09, 4:16PM CDT
Since hitting highs not seen in practically 14 years, the technology- and biotechnology-heavy Nasdaq Composite has been throttled, falling more than 5% on a trailing basis from the high point reached in early March. Comparatively speaking,...

Why Myriad Genetics (MYGN) is Poised to Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:50AM CDT
Myriad Genetics (MYGN) has seen a nice short-term history of beating earnings estimates, and looks poised to crush analyst expectations in its next earnings report as well.

RadNet, Inc. (RDNT) in Focus: Stock Surges 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:44AM CDT
RadNet, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 0

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 96

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 37

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 22

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 13

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 56

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading

Top 5 Most Recently Viewed Articles

SK Chemicals Delivers Sustainable Innovation at ECS 2025

Updated Category News Views 484

SK Chemicals at the European Coatings Show 2025 SK chemicals has proudly participated in the European Coatings Show (ECS) 2025, marking a significant moment for the company as it engages in marketing its innovative materials. This event is known for attracting key players in the coatings and paint sector, and this year was no exception, with over 1,000 exhibitors and more...

Continue Reading
Analyzing TJX Companies' Increased Short Interest Trends

Updated Category News Views 230

Understanding the Rise in TJX Companies' Short Interest The short interest for TJX Companies (NYSE: TJX) has seen a significant uptick, now standing at 14.55 million shares sold short, which constitutes 1.29% of its float. This marks a 21.7% increase since the prior reporting period. Given the current trading volume, traders would require approximately 2.49 days to cover...

Continue Reading
IGT Expands Collaboration with La Française des Jeux for Instant Tickets

Updated Category News Views 69

IGT Expands Collaboration with La Française des Jeux Company to deliver top-performing instant ticket games to one of the world's largest lotteries International Game Technology PLC (NYSE: IGT) has officially entered a three-year partnership with La Française des Jeux (FDJ), the esteemed operator of the French National Lottery. This significant agreement follows a...

Continue Reading
Archer Expands Footprint with New Manufacturing Facility Opening

Updated Category News Views 267

Archer Expands Footprint with New Manufacturing Facility Opening New state-of-the-art facility doubles manufacturing capacity and adds more than 200 local jobs Archer, one of the fastest-growing meat snack brands in the U.S., is celebrating a significant milestone with the grand opening of its new manufacturing facility. This latest addition in Vernon, California,...

Continue Reading
Bumble Faces Downgrade from KeyBanc Amid Revenue Concerns

Updated Category News Views 309

Bumble Inc (NASDAQ: BMBL) took a hit when KeyBanc downgraded its rating from 'Overweight' to 'Sector Weight', shaking the confidence of many investors. The downgrade was more than just a simple reassessment; it became a catalyst for a stock value decline in premarket trading that had traders watching their screens with bated breath. KeyBanc Downgrade: A Harbinger of...

Continue Reading